• Indomethacin: Practical Protocols for Cell Research

  2026-08-18

  Indomethacin is a nonsteroidal anti-inflammatory drug used to probe cyclooxygenase activity and related inflammation, PPAR, lipid metabolism, and membrane signaling questions. This guide supports controlled in vitro workflow setup, but its biochemical IC50 values should not be treated as cellular doses or evidence of therapeutic efficacy.

• CLCC1 and Herpesvirus Nuclear Egress

  2026-08-18

  The reference preprint identifies the host protein CLCC1 as an essential factor in the membrane-fusion step of herpesvirus nuclear egress, resolving a major gap left by studies of virally encoded budding machinery. CRISPR screening and cell-based phenotyping connect CLCC1 loss to perinuclear capsid accumulation, impaired nuclear pore insertion, and reduced viral production, while also suggesting an evolutionarily conserved membrane-remodeling mechanism.

• Asunaprevir (BMS-650032) Assay Guide

  2026-08-17

  A scenario-based guide to using Asunaprevir (BMS-650032), SKU A3195, in HCV RNA replication, cell viability, proliferation, and cytotoxicity workflows. It connects mechanism, solvent handling, controls, endpoint interpretation, and practical product-selection criteria to improve assay reproducibility.

• Recombinant Human Oncostatin M Assay Workflows

  2026-08-17

  Build reproducible proliferation and cytokine-response assays with a tag-free, highly active OSM preparation. This guide connects practical rh-Oncostatin M handling with phenotype-aware experimental design inspired by recent neuroinflammation research.

• N-MYC/eIF4G1 Survival Axis in inv(16) AML

  2026-08-16

  Peramangalam et al. identify a previously unrecognized MYCN enhancer and establish an N-MYC/eIF4G1 pathway that supports survival in inv(16) acute myeloid leukemia. By integrating transcriptomic, regulatory, cellular, and patient-derived model data, the study connects CBFβ-SMMHC disruption to a specific leukemic survival program and provides a framework for mechanism-led AML research.

• Candida krusei Forms Trigger Distinct BMEC Apoptosis

  2026-08-15

  The reference study shows that the yeast and hypha phases of Candida krusei both induce apoptosis in bovine mammary epithelial cells, but through different dominant pathways. Its phase-resolved co-culture design links yeast-associated injury to mitochondrial dysfunction and hypha-associated injury to death ligand/receptor signaling, while identifying TLR2/ERK and JNK/ERK signaling as shared regulatory axes.

• miR-18a–ALOXE3 Signaling in Glioblastoma

  2026-08-14

  The reference study identifies a miR-18a/ALOXE3 regulatory axis that promotes glioblastoma by weakening ferroptotic cell death and enhancing tumor-cell migration through 12-HETE signaling. Its integrated genetic, cellular, lipid-mediator, and orthotopic-model evidence positions ALOXE3 as a mechanistic link between lipid metabolism, p53-associated ferroptosis, and glioblastoma progression.

• Spinal Astrocytic EAATs in Breakthrough Cancer Pain

  2026-08-14

  Jiang and colleagues developed a recurrent endothelin-1 mouse model of breakthrough cancer pain and identified coordinated changes in spinal astrocytic EAATs and connexin 43 signaling. Their findings position glutamate transport and Cx43-associated gap junction activity as experimentally tractable mechanisms, while highlighting Gap26 as a pharmacological tool for testing this relationship.

• LEE011 succinate: CDK Inhibitor Workflow

  2026-08-13

  Build more informative cancer research assays with LEE011 succinate, a selective CDK4/6 inhibitor suited to proliferation, cell-cycle, and combination studies. This guide connects practical dosing and plate-based workflows with pH-aware formulation controls and troubleshooting strategies.

• Nifedipine: Calcium Signaling Meets Liver Pharmacology

  2026-08-13

  Nifedipine (BAY-a-1040) is more than an L-type calcium channel blocker: it is a precise perturbation tool for separating calcium-dependent phenotypes from hepatic metabolic adaptation. This guide connects calcium influx inhibition with PXR–CYP assay design while defining practical controls, handling, and translational limits.

• PR-619: Reversible DUB Inhibitor

  2026-08-12

  PR-619 is a cell-permeable, reversible deubiquitylating enzymes inhibitor for ubiquitination pathway research. It broadly inhibits cysteine-dependent DUBs, increases cellular ubiquitinated proteins without directly blocking proteasomal catalytic activity, and supports cancer biology, autophagy, and neurodegeneration studies.

• Octenidine dihydrochloride Research Workflows

  2026-08-12

  Octenidine dihydrochloride provides a practical benchmark for membrane-focused antimicrobial assays, from planktonic killing and biofilm testing to comparative antiseptic research. This guide pairs preparation details with assay controls, troubleshooting strategies, and recent gemini-quaternary-ammonium findings to help researchers distinguish solubility, exposure, and biological effects.

• Cyanin Chloride in a HaCaT Psoriasis Model

  2026-08-11

  The 2024 study by Kim and colleagues examines cyanin chloride in inflammatory and barrier-defective skin-cell models, combining antioxidant assays, macrophage inflammation testing, cytokine-stimulated HaCaT keratinocytes, STAT3 analysis, and transepithelial electrical resistance measurements. Its central contribution is to connect suppression of psoriasis-associated inflammatory signals with restoration of epithelial barrier markers, while also clarifying the limits of translating in vitro findings into therapeutic claims.

• Agatoxin-Sensitive Channels in Cardiac Vagal Neurons

  2026-08-11

  Wang, Irnaten, and Mendelowitz used whole-cell patch-clamp recordings and selective calcium-channel antagonists to show that nicotine activates cardiac vagal neurons through agatoxin-IVA-sensitive voltage-dependent calcium channels. The study separates presynaptic facilitation of glutamatergic release from the postsynaptic inward current, providing a focused pharmacological framework for analyzing nicotinic control of cardiac autonomic circuits.

• BGJ398: FGFR Workflow for Cancer Research

  2026-08-10

  BGJ398 (NVP-BGJ398) combines nanomolar FGFR1/2/3 potency with a practical workflow for pathway validation, cancer-cell response profiling, and carefully controlled developmental explant studies. This guide connects target engagement, apoptosis readouts, species-aware assay design, and troubleshooting without treating preclinical findings as clinical guidance.

15893 records 1/1060 page Next 12345 下5页 Last page